PI3K-AKT-mTOR signaling and therapeutic opportunities in prostate cancer (WP3844)

Homo sapiens

This pathway is based on figure 1 from Merritt et al. (See Bibliography). The PI3K-AKT-mTOR signaling pathway has been shown to have a significant correlation with the development of castration-resistant prostate cancer. The signaling pathway regulates many cellular processes such as protein synthesis, proliferation, survival, metabolism, and differentiation, all factors that would increase a cancerous cell's ability to survive. Scientists have explored the use of various inhibitors for different parts of the signaling pathway, and have been faced with varying success. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP3844 CPTAC Assay Portal]

Authors

AAR&Co , Friederike Ehrhart , Alex Pico , Kristina Hanspers , Martina Summer-Kutmon , Liling , Denise Slenter , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

CPTAC PancCanNet

Annotations

Pathway Ontology

disease pathway cancer pathway signaling pathway phosphatidylinositol 3-kinase-Akt signaling pathway phosphatidylinositol 3-kinase signaling pathway

Disease Ontology

prostate cancer

Participants

Label Type Compact URI Comment
PIP3 Metabolite hmdb:HMDB0010147
PIP2 Metabolite hmdb:HMDB0010035
TSC2 GeneProduct ensembl:ENSG00000103197
MLST8 GeneProduct ensembl:ENSG00000167965
eNOS GeneProduct ensembl:ENSG00000164867
GRB10 GeneProduct ensembl:ENSG00000106070
RAPTOR GeneProduct ensembl:ENSG00000141564
FOXO3 GeneProduct ensembl:ENSG00000118689
AKT GeneProduct ensembl:ENSG00000142208
TFEB GeneProduct ensembl:ENSG00000112561
FOXO1 GeneProduct ensembl:ENSG00000150907
FIP200 GeneProduct ensembl:ENSG00000023287
PTEN GeneProduct ensembl:ENSG00000171862
BAD GeneProduct ensembl:ENSG00000002330
ULK1 GeneProduct ensembl:ENSG00000177169
PDK1 GeneProduct ensembl:ENSG00000152256
4EBP1 GeneProduct ensembl:ENSG00000187840
MTOR GeneProduct ensembl:ENSG00000198793
p27 GeneProduct ensembl:ENSG00000111276
GSK3B GeneProduct ensembl:ENSG00000082701
ATG13 GeneProduct ensembl:ENSG00000175224
RHEB GeneProduct ensembl:ENSG00000106615
S6K1 GeneProduct ensembl:ENSG00000082701
RICTOR GeneProduct ensembl:ENSG00000164327
FOXO4 GeneProduct ensembl:ENSG00000184481
PIK3CA GeneProduct ensembl:ENSG00000121879
PIK3CB GeneProduct ensembl:ENSG00000051382
PIK3R1 GeneProduct ensembl:ENSG00000145675
PIK3R2 GeneProduct ensembl:ENSG00000105647
PIK3R3 GeneProduct ensembl:ENSG00000117461
PIK3CG GeneProduct ensembl:ENSG00000105851
HRAS GeneProduct ensembl:ENSG00000174775
NRAS GeneProduct ensembl:ENSG00000213281
KRAS GeneProduct ensembl:ENSG00000133703
MAPKAP1 GeneProduct ensembl:ENSG00000119487

References

  1. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Edlind MP, Hsieh AC. Asian J Androl. 2014;16(3):378–86. PubMed Europe PMC Scholia